Abbonarsi

Phytochemicals targeting lncRNAs: A novel direction for neuroprotection in neurological disorders - 29/04/23

Doi : 10.1016/j.biopha.2023.114692 
Hang Zhao a, 1, Lin Wang b, Lijuan Zhang c, , 2 , Hongyu Zhao b, , 2
a Department of Family Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China 
b Department of Emergency medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China 
c Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China 

Correspondence to: Departments of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang 110000, Liaoning, PR China. Departments of Obstetrics and Gynecology, Shengjing Hospital of China Medical University No. 39 Huaxiang Road, Tiexi District Shenyang Liaoning 110000 PR China ⁎⁎ Correspondence to: Department of Emergency medicine, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang 110000, Liaoning, PR China. Department of Emergency medicine, Shengjing Hospital of China Medical University No. 39 Huaxiang Road, Tiexi District Shenyang Liaoning 110000 PR China

Abstract

Neurological disorders with various etiologies impacting the nervous system are prevalent in clinical practice. Long non-coding RNA (lncRNA) molecules are functional RNA molecules exceeding 200 nucleotides in length that do not encode proteins, but participate in essential activities. Research indicates that lncRNAs may contribute to the pathogenesis of neurological disorders, and may be potential targets for their treatment. Phytochemicals in traditional Chinese herbal medicine (CHM) have been found to exert neuroprotective effects by targeting lncRNAs and regulating gene expression and various signaling pathways. We aim to establish the development status and neuroprotective mechanism of phytochemicals that target lncRNAs through a thorough literature review. A total of 369 articles were retrieved through manual and electronic searches of PubMed, Web of Science, Scopus and CNKI databases from inception to September 2022. The search utilized combinations of natural products, lncRNAs, neurological disorders, and neuroprotective effects as keywords. The included studies, a total of 31 preclinical trials, were critically reviewed to present the current situation and the progress in phytochemical-targeted lncRNAs in neuroprotection. Phytochemicals have demonstrated neuroprotective effects in preclinical studies of various neurological disorders by regulating lncRNAs. These disorders include arteriosclerotic ischemia-reperfusion injury, ischemic/hemorrhagic stroke, Alzheimer's disease, Parkinson's disease, glioma, peripheral nerve injury, post-stroke depression, and depression. Several phytochemicals exert neuroprotective roles through mechanisms such as anti-inflammatory, antioxidant, anti-apoptosis, autophagy regulation, and antagonism of Aβ-induced neurotoxicity. Some phytochemicals targeted lncRNAs and served a neuroprotective role by regulating microRNA and mRNA expression. The emergence of lncRNAs as pathological regulators provides a novel direction for the study of phytochemicals in CHM. Elucidating the mechanism of phytochemicals regulating lncRNAs will help to identify new therapeutic targets and promote their application in precision medicine.

Il testo completo di questo articolo è disponibile in PDF.

Graphical Abstract




ga1

Il testo completo di questo articolo è disponibile in PDF.

Highlights

31 papers were reviewed to elucidate phytochemical-targeted lncRNAs in neuroprotection.
Phytochemicals could be a new candidate drug for treating neurological disorders.
Anti-inflammatory, anti-oxidative, anti-apoptotic effects are common mechanisms of phytochemicals regulate lncRNAs.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : AD, AoSMCs/HA-VSMCs, AS-IV, ATGL, BMDMs, BMECs, BMVEC, CHOP, EGFR, ELF5, EndMT, ERK, ERS, EZH2, FGF-2, GBM, GP, GPx, HFD, HIF-1α, HT22, HUVEC, ICAM‑1, ICH, IL, JNK, LDH, LDL, MCP‑1, MCAO, MDA, MPP + , MPTP, mTOR, NF-κB, NGR1, NLRP3, OGD, PCA, PCNA, PD, PPARγ, ROS, SNCA, SD, SOD, SYB, TGF-β, TH, TMP, TNF, VEGFA, VSMCs, ZNF217

Keywords : Neurological disorders, LncRNAs, Phytochemicals, Traditional Chinese herbal medicine, Pharmacology, Neuroprotection


Mappa


© 2023  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 162

Articolo 114692- giugno 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
  • Da Qian, Jialu Li, Mingyao Huang, Qiuxia Cui, Xiaozhen Liu, Kailv Sun
| Articolo seguente Articolo seguente
  • Cell signaling pathways based on vitamin C and their application in cancer therapy
  • Dianfa Fan, Xiyu Liu, Zhen Shen, Pan Wu, Liping Zhong, Faquan Lin

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.